pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
onclive·May 5·1 min read
save

Experts stress seamless coordination for relapsed multiple myeloma patients across academic and community clinics

May 5, 2026·read at onclive ↗Neutral

In a recent opinion segment, Dr. Ajay K. Nooka convened a discussion with Dr. Noopur S. Raje and Dr. Surbhi Sidana about how to best coordinate care for patients with relapsed and refractory multiple myeloma.

The panel emphasized the need for smooth collaboration between academic centers and community practices, especially during critical transition points before and after patients receive advanced therapies.

They argued that consistent communication and shared treatment planning can improve outcomes and reduce barriers for patients navigating complex therapy pathways.

source

This writeup was produced by pharmadog from original reporting by onclive.

Original headline: “Coordinating Care in Multiple Myeloma Across Practice Settings”

read at onclive ↗
1,584 words · retrieved May 8
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
JOURNEY
drugs
icosapent ethyl3HNSCCKEYTRUDAKEYTRUDA QLEXNovel Therapeuticpembrolizumabzenocutuzumab
topics
Oncology21Multiple Myeloma17Breast Cancer6HER26NSCLC3TROP-23Antibody-Drug Conjugate (ADC)2Hematology2Oncolytic Virus2Prostate Cancer2Radioligand Therapy2AMDAMLBispecific AntibodyDiabetic Macular EdemaEGFREndocrinology & MetabolismGlioblastomaImmunologyKRASMelanomaMonoclonal AntibodyNeurologyPsychiatry & CNSSmall Molecule

related stories

  • May 5Dr Kuykendall on the Evolving JAK Inhibitor and Transplant Considerations in Myelofibrosisonclive
  • May 8Dr Randall on Long-Term Responses and Functional Benefits With Pimicotinib in TGCTonclive
  • May 8Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast Canceronclive
  • May 8Dr Sznol on the Nuances of Recommending Neoadjuvant Therapy in Metastatic Melanomaonclive
  • May 8Biomarker-Directed Therapies Move the GI Oncology Paradigm Beyond a One-Size-Fits-All Approach: With Michael J. Pishvaian, MD, PhDonclive